HUNT VALLEY, Md., July 25, 2017 /PRNewswire/ -- Mastix LLC, a leading manufacturer of innovative functional supplement
"The granting of this notice of allowance for our novel chewing gum dosage form validates the innovative nature of our platform technology and positions us well to offer our customers and consumers an alternative delivery system to pills, capsules and beverages that is widely acceptable and very familiar," said Bob Estey, CEO of Mastix. "We have the unique ability to incorporate either a single active ingredient, or multiple active ingredients, into the gum tablets we make to provide our customers with truly custom chewing gum products that will now be patent protected. Consumers are actively seeking alternative delivery vehicles for the many pharmaceutical and supplement products they currently take as pills or capsules. Chewing gum is a convenient and discrete way for consumers to quickly and efficiently deliver the benefits they expect from the products they use to improve their health and wellness. The extensive clinical studies the US Military performed on our caffeine gum proved that gum delivered through the oral mucosa is up to five times faster than swallowing pills or capsules while also maintaining high bioavailability of the active."
In addition to its proprietary CBD gum (www.medcbdx.com), Mastix offers custom development, contract manufacturing and private label for its chewing gum, lozenge and chewable tablet products. Mastix has developed tableted products in a wide range of active ingredients including dietary supplements, herbal extracts, probiotics and cannabinoids, and is best known as the supplier of caffeine chewing gum for the US Military ration kits.
About Mastix LLC Mastix LLC develops, manufactures and markets niche functional food and dietary supplement products in chewing gum, chewable tablet and lozenge dosage formats. Mastix manufactures its products in full compliance with FDA GMP regulations.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: The statements presented in this press release have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.
LEGAL DISCLOSUREMastix LLC does not develop, manufacture, sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
View original content:http://www.prnewswire.com/news-releases/new-us-patent-allowance-granted-to-mastix-llc-for-a-new-chewing-gum-manufacturing-method-incorporating-cannabinoids-300493344.html
SOURCE Mastix LLC
Subscribe to our Free Newsletters!
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...View All